**Name of Journal: World Journal of Gastroenterology**

**ESPS Manuscript NO: 18697**

**Manuscript Type: TOPIC HIGHLIGHTS**

**2015 Advances in Hepatitis B virus**

**hepatitis B virus burden in developing countries**

Zampino R *et al*. HBV in developing countries

Rosa Zampino, Adriana Boemio, Caterina Sagnelli, Loredana Alessio, Luigi Elio Adinolfi, Evangelista Sagnelli, Nicola Coppola

**Rosa Zampino, Adriana Boemio, Luigi Elio Adinolfi,** Department of Medical, Surgical, Neurological, Metabolic, and Geriatric Sciences, Second University of Naples, 80135 Naples, Italy

 **Caterina Sagnelli,** Department of Clinical and Experimental Medicine and Surgery "F. Magrassi e A. Lanzara", Second University of Naples, 80135 Naples, Italy

**Loredana Alessio, Nicola Coppola,** Section of Infectious Diseases, Department of Mental Health and Public Medicine, Second University of Naples,80135 Naples, Italy

**Evangelista Sagnelli,** Department of Mental Health and Public Medicine, Second University of Naples, Honorary Professor of Infectious Diseases, 80135 Naples, Italy

**Author contributions:** Zampino R conceived and drafted the article and approved the final version; Boemio A, Alessio L and Sagnelli C reviewed the literature, contributed to drafting the article and approved the final version; Adinolfi LE, Sagnelli E and Coppola N, critically reviewed the manuscript and approved the final version.

**Conflict-of-interest statement:** None of the authors have any conflict of interest in connection with this study.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Correspondence to: Rosa Zampino, MD, PhD,** Department of Medical, Surgical, Neurological, Metabolic, and Geriatric Sciences, Second University of Naples, Via Pansini, 5, 80135 Naples, Italy. rosa.zampino@unina2.it

**Telephone:** +39-81-5666708

**Fax:** +39-81-5666707

**Received:** April 26, 2015

**Peer-review started:** April 27, 2015

**First decision:** July 13, 2015

**Revised:** July 23, 2015

**Accepted:** September 28, 2015

**Article in press:**

**Published online:**

**Abstract**

Hepatitis B virus (HBV) infection has shown an intermediate or high endemicity level in low-income countries over the last five decades. In recent years, however, the incidence of acute hepatitis B and the prevalence of hepatitis B surface antigen chronic carriers have decreased in several countries because of the HBV universal vaccination programs started in the nineties. Some countries, however, are still unable to implement these programs, particularly in their hyperendemic rural areas. The diffusion of HBV infection is still wide in several low-income countries where the prevention, management and treatment of HBV infection are a heavy burden for the governments and healthcare authorities. Of note, the information on the HBV epidemiology is scanty in numerous eastern European and Latin-American countries. The studies on molecular epidemiology performed in some countries provide an important contribution for a more comprehensive knowledge of HBV epidemiology, and phylogenetic studies provide information on the impact of recent and older migratory flows.

**Key words**: Hepatitis B virus; Molecular epidemiology; Prevention; Developing countries; Chronic hepatitis

**© The Author(s) 2015.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** hepatitis B virus (HBV) infection is a heavy burden in most developing countries because of its wide spread, particularly in rural areas, and the high cost of prevention, management, and treatment. Therefore, a greater effort should be made towards implementing universal vaccination programs as they have been demonstrated to be effective in reducing the incidence of acute hepatitis B and the prevalence of hepatitis B surface antigen chronic carriers. In several low-income countries, an improvement in the current knowledge of HBV epidemiology, molecular epidemiology, HBV replication and co-infection with other viruses such as hepatitis C virus and human immunodeficiency virus is strongly desired.

Zampino R, Boemio A, Sagnelli C, Alessio L, Adinolfi LE, Sagnelli E, Coppola N. hepatitis B virus burden in developing countries. *World J Gastroenterol* 2015; In press

**Introduction**

Nearly 240 million people worldwide carry hepatitis B virus (HBV) infection[1], associated in nearly half of the cases with a chronic liver illness. The progression of liver disease to the more severe forms and the development and complications of hepatocellular carcinoma (HCC) entail a heavy burden for low-income countries. Also political and socio-economic problems make it difficult, at times impossible, to deal with the prevention, management and treatment of HBV infection and associated diseases. This review article focuses on the epidemiology and prevention of HBV infection in low-income countries with an intermediate or high endemicity level.

**AFRICA (epidemiology, molecular biology, prevention)**

***Epidemiology***

Africa is on the whole considered to have a high HBV endemicity. HBV infection is hyperendemic [> 8% of hepatitis B surface antigen (HBsAg) chronic carriers in the general population] only in some sub-Saharan countries such as Nigeria, Namibia, Gabon, Cameroon, Burkina Faso. Other countries like Kenya, Zambia, The Ivory Coast, Liberia, Sierra Leone and Senegal are considered areas of intermediate endemicity (2%–8%), while Egypt, Tunisia, Algeria and Morocco, located in the north of the continent, show a low endemicity level (< 2%)[2]. The prevalences of HBV carriers and genotype distribution in some African countries are listed in Table 1.

The endemicity level varies also in different districts and in different target groups in the same country, *e.g.*, in Burkina Faso, one of the African countries with a high endemicity[3], the HBV overall prevalence is estimated at around 14.5%[4], some authors having reported a level of 12.1% in the health district of Nanoro[5], 18% in blood donors of Nouna, 11% in blood donors and 9.3% in pregnant women in the district of Ouagadougou[6,7]. In Nigeria, HBsAg seropositivity is estimated at around 13.6%, but higher rates have been found in surgeons (25.7%)[8], voluntary blood donors (23.4%)[9] and infants (16.3%)[10]. In Cameroon, recent studies reported an HBV prevalence of 10.1% and 12.1% in blood donors referring to two hospital blood banks[11,12] and of nearly 8% in pregnant women[13-15].

HBsAg-positive age-specific rates were estimated on a global level for 1990 and 2005 using an empirical Bayesian hierarchical model. A 12% prevalence was observed in 1990 in children and adolescents aged up to 19 years in western sub-Saharan African countries, the highest rate documented in the world in this age class, and only slightly decreasing in 2005. In southern sub-Saharan Africa, chronic HBV infection among younger age groups (0–14 years) had increased in 2005, with a prevalence of 8%–9% in females. Also in eastern sub-Saharan African countries, the HBsAg positivity rate had increased in the younger ages over time, whereas no significant changes were detected in the older age groups. An evident decrease in the HBV endemicity was observed in central sub-Saharan Africa, from a high endemicity in the aged 0-34 in 1990 to intermediate values in all ages in 2005. Also in northern Africa and the Middle East regions, the HBV prevalence decreased from 1990 to 2005, particularly among males aged up to 34 years[16].

Of note, the epidemiology in Africa is characterized by a much higher HBsAg prevalence in rural than in urban areas[17,18] and by a greater risk for males of becoming HBV chronic carriers, with a male to female ratio ranging from 1.1:1 to 3:1 and increasing with the increase in age[19-31]. The higher percentage of HBsAg-positive males harboring HBV chronic infection may be the result of differences in tribal and sexual behaviors between males and females[32].

Compared with the adult HBsAg chronic carriers from Southeast Asia, another hyperendemic area, those from Africa show a lower rate of HBeAg positivity. In African countries, 20%–30% of subjects infected by HBV in their early childhood become chronic carriers and only 10% of them remain HBeAg-positive during adolescence. The majority of HBeAg-positive subjects lose HBeAg quickly, at an annual rate of 14%–16%[33]. As is the case in Euro-Mediterranean countries, also in Africa a large majority (> 85%) of patients with a biochemically and histologically active disease are HBeAg-negative[34,35]. In addition, the rate of HBeAg-positive cases found in HBsAg-positive pregnant women was < 1% in Ethiopia, 1.16% in Ghana[36], 1.39% in Nigeria[37], 3.3% in Zimbabwe[38], 4.6% in South Africa[39], 9.5% in Senegal[40], 16.1% in Zambia[41], and 24% in southern Tanzania[42]. The low rate of HBeAg positivity in HBsAg-positive pregnant women in most African countries correlates with the low rate of perinatal transmission observed in Africa[43].

## The data from 18 African countries showed a median HBsAg-positive prevalence of 12.1% in human immunodeficiency virus (HIV)-infected individuals (range 3.9%–70.3%)[44]. In sub-Saharan Africa, the prevalence of patients with HIV/HBV co-infection varies from 0% to 28.4% in different studies[45-49], with a median rate of 3.8% (0%–13%) in pregnant women and 7.4% (1.2%–7.8%) in children and young adults aged from 18 months to 17 years. Western African countries seem to have the highest co-infection rates (median: 11.5%) in the continent, southern African countries the second highest (median 5.4%), and eastern African countries the lowest (median 4.1%), with a wide variation in single countries[50]. Also the prevalence of cases with occult HBV infection in HIV-infected patients varies largely across the continent, the available information, mostly from southern and western Africa, stating rates from 10% to 33%[51-56].

In African countries, children are at a high risk of acquiring HBV infection. The annual seroconversion rates to HBV markers varied from 10.2%-60.5% in children aged 1-10 years in Somalia, with the highest rate in those with a lower socio-economic condition[23]. The highest rate of children with HBV infection was 15.7% in children aged 5 and 6 years in a study from South Africa[57]. Children acquire HBV infection most frequently by parenteral horizontal transmission[58] from parents or siblings, as clearly demonstrated by phylogenetic analysis in Gambian families where HBV transmission occurred in at least two-thirds of the families investigated[59]. Unsafe sharing in the daily practices of toiletries and sharpening, cutting, scraping or scratching objects accounts for such a high horizontal transmission. In addition, cultural practices like scarification and tattooing and promiscuous sexual activity greatly increase the risk of HBV infection[29,60-63].

HBV transmission through the transfusion of blood or blood products still occurs[58] and is believed to have an epidemiological impact in some areas in sub-Saharan Africa[64]. Over the last decade, the United States President’s Emergency Plan for AIDS Relief and the Global Fund have supported blood safety programs in 38 sub-Saharan African countries. The median percentage of HBV markers in blood donations was 7.1% in 2000/2004 and 4.4% in 2010/2011. From 2000/2004 to 2010/2011, 28 (82%) of the 34 reporting countries described a statistically significant decrease in HBsAg marker-reactive donations. Overall, the combined data from the 34 countries showed a 37% decrease in the HBsAg-reactive donations[65].

***Molecular epidemiology***

Five HBV genotypes are more frequently detected In Africa, A, B, C, D, E (Table 1)[2]. Despite the limited number of studies, a trend in their distribution is emerging. Genotype A predominates in southern and eastern Africa, genotype D in northern Africa[2] and genotype E in the vast region from Senegal to Namibia and eastward to the Central African Republic. HBV/E is the most frequent genotype found in the Central African Republic, the Democratic Republic of the Congo, Benin, Togo and Nigeria[2,66,67]. Recombinants of HBV genotypes have also been detected, an A and E recombinant in Cameroon[66] and western Africa[67] and an A and D recombinant in healthy black African adults positive for hepatitis B surface antibody alone [68].

Most of genotype A sequenced in Africa belongs to subgenotype A1, which is mainly found in southern and eastern Africa, including South Africa, Malawi, Tanzania, Uganda, the Democratic Republic of the Congo and Somalia. This subgenotype has been frequently detected also in southern Asia (India, The Philippines, Bangladesh, Nepal), supporting the hypothesis that this subgenotype was introduced to Asia through the intensive trade and frequent travels from eastern Africa[69-73].

Subgenotype A2, mainly isolated in South Africa, resembles some European isolates and the hypothesis that Portuguese sailors probably introduced this subgenotype to Europe in the 16th and 17th century has been formulated[73]. Genotype E prevails in native populations of western and central Africa[2]. All genotype E strains have the same characteristic, an in-frame deletion of three nucleotides in the 5’ pre-S1 region, a signature pattern of amino acids in the pre-S1 region and a serological subtype formulated as *ayw4.* The low genetic diversity over large geographical areas suggests that HBV/E may have a short evolutionary history and a recent introduction to African countries [2,74].

HBV genotype D is the most prevalent in northern Africa, particularly subgenotypes D1[75,76] and D7[76,77], but it is also diffuse worldwide. A recent comprehensive reconstruction of the phylogeography of HBV genotype D in the European Mediterranean basin indicates that it originated in the second half of the 19th century in India[78,79].

***Prevention***

Vaccination is essential to control HBV infection. Thanks to the Expanded Programme on Immunization started in 1995 in some African countries, such as South Africa, the monovalent anti-HBV vaccine continues to be administered at 6, 10, and 14 weeks of age and the rate of HBV infection and HCC in children shows a clear tendency to decrease[80].

HBV vaccination in HIV-positive African populations provides a moderately lower response rate than in the general African populations, but, as in other countries, revaccination of non-responders increases the response rate to 95%[81].

**ASIA (epidemiology, molecular biology, prevention)**

***Epidemiology***

Southwestern Asia, also known as the Arabian region, accounts for 10% of the Asian territory. The Arabian peninsula, including Saudi Arabia, Yemen, Oman, Bahrain, the United Arab Emirates (UAE) and Kuwait[82-84], shows an HBsAg-positive prevalence ranging from 1.5% to over 8%[16]. In particular, this prevalence ranges from 1.5% to 2.6% in Saudi Arabia, is reported to be 5.1% in blood donors in Yemen, the poorest country of the Arabian peninsula, 3.5% in volunteer blood donors in Kuwait and to range between 2% and 7% in the general population in UAE[85-88]. The Levant (Sham) Arabian region comprises Syria, Iraq, Lebanon, Jordan and the Gaza Strip. The HBsAg-positive prevalence is 0.6% in the general population in Iraq[89], 1.6% in volunteer blood donors in Lebanon[90] and 1.4 % in blood donors in Jordan[91]. No data are available for Syria at present, apart from its classification as a geographical area with an intermediate endemicity in the report by Lavanchy[86]. The HBsAg-positive prevalence in the Gaza Strip is 3.5% in the general population and 3.8% in blood donors[92]. Arab countries have implemented the WHO-recommended Expanded Programme on Immunization, and HBV vaccination programs started in these countries have now covered a large proportion of their population, successfully reducing the HBV endemicity. In Saudi Arabia, the first Arab country to adopt an HBV vaccination program[93], a steady decline in the HBsAg-positive prevalence has been observed in children aged 1–12 years, from 7% in 1989, to 0.31% in 1997 and 0% in 2008[94,95].

In Cambodia, one of the western Pacific countries, the HBV prevalence was 4.6% in the adult population[96] and 6.3% in blood donors (Ministry of Health in Cambodia, 2013, unpublished. data). In this country, high anti-HBc rates have been reported, 58.6% and 72.4% in different studies[97,98], suggesting a principal role played in the past by horizontal transmission in childhood and adulthood.

The HBsAg-positive prevalence was 3.6% in subjects aged 18-79 years in Singapore in 2010, and HBeAg was detected in 4.2% of the HBsAg-positive cases. The national childhood HBV vaccination program adopted in this country has shown a great impact in reducing the spread of HBV infection [99].

In China, thanks to the universal HBV immunization program of newborn babies initiated in 1992, the prevalence of HBsAg carriers decreased from 9.8% observed in 1992 to 7.18% registered in 2006[100]. Of note, the vaccination coverage rate at the end of 2005 was 20% lower in rural areas than in the urban areas, a difference that has steadily decreased in recent years. Despite the suboptimal coverage, the prevalence of anti-HBs was higher in fully immunized children (63.2%–74.3%) than in non-immunized subjects (21.1%–34.8%)[101]. As a result of the universal HBV vaccination campaign, China has gone from a high to an intermediate endemicity level in a short period of time[102]. At present, however, the HBV prevalence in some high-risk groups is very high, *e.g.*, 11.9% in hemodialysis patients[103] and 12.5% in HIV-positive subjects[104].

In South Korea the HBsAg-positive seroprevalence is 4%, slightly higher in the southern than in the central provinces. In the last decade, however, the universal vaccination program has brought about an impressive reduction in HBsAg positivity documented in the younger population, from 2.2% to 0.12%[105,106].

In Kazakhstan, an HBV seroprevalence of 3.8% has been documented, with a peak in the adult population aged 30-49 (6.3%) and lower rates in the aged 10-29 (2.5%) and in subjects over 50 (1.7%)[107].

In India, the estimated HBsAg-positive prevalence is 3.1% in the non-tribal population and 11.85% in tribal populations[108], with wide geographical variations within this subcontinent due to differences in socioeconomic status, religion, culture and tribal practices.

The prevalences of HBV infection and genotype distribution in some Asian countries are shown in Table 2.

***Molecular epidemiology***

# In the Arabian countries HBV genotype D predominates, particularly, subgenotypes D1 and D3[109]. Patients living on the northern coast of the Persian Gulf are infected mainly with HBV subgenotype D1, spread widely by ancient migrations from Iran, Syria, and Turkey[110].

# In China, HBV genotypes B and C, and in particular subgenotypes B2 and C2, predominate, with some geographical differences. Genotype B is more frequent in southern China and genotype C in the north of the country. In some regions of northern China subgenotype C2 is predominant, whereas subgenotype C1 is more frequent than C2 in southern China. Recombinant C/D1 and C/D2 have been found to be predominant in the Qinghai-Tibet Plateau and in western China, indicating that the spread of these two recombinants may have an ethnic origin[111-118]. Other HBV subgenotypes, such as C5 and C7, possibly introduced from the southeastern Asian countries, have been infrequently detected in China[119]. Compared with HBV subgenotype B, subgenotype C shows a lower replicative activity in young patients and harbours higher frequencies of HCC-associated mutations [120].

In Pakistan HBV genotype D predominates, particularly subgenotypes D1 and D3 and a B/D recombinant plays a marginal role, being responsible for 3.5% of the cases. It has been suggested that genotype D achieved its wide distribution in ancient times associated with the ancient history of the civilizations in this region[121].

Taking into consideration the HBV-host co-evolution, the diverse Indian population provides an excellent opportunity for further studies to investigate some underpinnings of the HBV diversity. Of the three HBV genotypes found in India, namely D, A and C, genotype D is predominant, whereas all the HBV/A and HBV/C isolates discovered in India belong to subgenotype A1 and C1, respectively; the genotype D strains are divergent and classified into 5 distinct subgenotypes, D1, D2, D3, D5 and D9, with a different geographical distribution[122-125].

***Prevention***

The WHO estimates that Asia is the continent with the highest rate of HBsAg carriers in the world, with an overall prevalence in the adult population of over 8%. In order to prevent HBV infection and its associated diseases, several Asian countries have started vaccination programs[126]. An extensive program (China GAVI Hepatitis B Immunization Project) was started in China in 2002 in all the Chinese provinces to prevent HBV transmission to newborn babies in order to decrease over time the circulation of HBV in the country and reduce the heavy burden of liver cirrhosis and HCC. Although the program has not yet reached some rural areas, HBV vaccination covers more than 75% of newborn babies and the rate of HBsAg positivity has decreased from 10% to 1%[127]. This project has certainly required a strong political, social and economic commitment, but the results obtained to date are truly impressive.

**EASTERN EUROPE (epidemiology, molecular biology, prevention)**

***Epidemiology***

The low number of epidemiological studies on HBV infection performed in eastern Europe does not allow conclusive statements to be made on the spread of HBV infection and on the level of application of universal vaccination in this large geographical area. The available data from eastern European countries show higher HBsAg-positive prevalences than in western Europe[128-131](Table 3), but the ongoing universal HBV vaccination campaign in rural and urban areas of the single countries will reduce this gap in the near future. In fact, in a recent study from Bulgaria, the HBsAg-positive prevalence in individuals aged 19 or less, targeted by HBV vaccination, was significantly lower than that found in non-vaccinated individuals aged over 20 (1% *vs* 4.8%)[132]. The HBsAg-positive seroprevalence in the general population was 3.8% in studies performed in Bulgaria[133,134], 5.6% in Romania[135] and from 4.4%-13% in different studies in Serbia[136-138], with wide variations within single countries that reflect the different socio-economic conditions between rural and urban areas[135]. In these studies, males showed higher rates of HBsAg positivity than females.

Although introduced in 1995, HBV vaccination has not as yet significantly reduced the high HBV endemicity level in Albania[139-141], where HBsAg positivity in the general population is over 9% and the overall risk of becoming infected exceeds 60%[142-145]. In Poland, an incidence of acute hepatitis B of almost 4 cases per 100000 inhabitants was registered both in 2011 and 2012, suggesting a stable spread of HBV infection in this country[146]. In the adult population in Croatia, HBV seropositivity increased with the increase in age, from 1.7% to 15.8%, and was higher in subjects from rural areas than from urban areas (10.7% *vs* 6.1%)[147]. The incidence of acute hepatitis B in Russia was 7.6 per 100000 inhabitants in 2009, with wide variations across the country[148].

***Molecular epidemiology***

HBV genotypes A and D are those most frequently detected in eastern Europe (Table 3)[149], genotype D being responsible for 70%–80% of the HBV infections occurring in the northern and central areas and in eastern Mediterranean countries[128,150-153]. In fact, HBV genotype D predominates in Romania (67%), Lithuania (54%), Serbia (82%), Croatia (80%), Albania (92%) and Russia (93%), whereas genotype A predominates in Poland (77%) and in the Czech Republic (67%), two countries with similar ethnic backgrounds and a small proportion of immigrants (3%–4%)[79,128,152,154,155].

HBV genotype A and D, and subgenotypes D1 and A2 in particular, are those more frequently detected in Bulgaria[156]. Using a phylodynamic approach, the beginning of the spread of D1 in this country dated back to the early 1980s[78,156], whereas the strains analyzed of subgenotype A2 dated back to 1996. HBV genotype A is frequent in central and northern Europe, where the HBV spread is mainly sustained by sexual transmission[157-159], and in Bulgaria, which has a crossroads position between western and eastern Europe favoring the introduction of new subgenotypes [156].

More than 70% of Albanian HBsAg carriers are infected with HBV D2 subgenotype, suggesting an epidemiological relationship between Albania and northeastern European countries of the former USSR, rather than from other Mediterranean countries, where HBV subgenotypes D1 and D3 predominate [79,160,161].

Hungary shows an almost equal distribution of HBV genotypes A and D, probably due to its central position between western and eastern Europe [152].

***Prevention***

In 2009, Nardone *et al*[162] published a report on the HBV epidemiology in 10 European countries in relation to the application of the vaccination policies. At the time of publication of this report, HBV universal vaccination programs recommended by the WHO were in progress in different countries of eastern Europe (the Czech Republic, Romania and Slovakia), but coverage differed between countries, most probably reflecting the difficulty to reach people living in rural areas in some countries (Romania, Slovakia).

In Poland, HBV vaccination of newborn babies is active and no new HBV cases in childhood and adolescence have been registered, whereas non-vaccinated subjects aged 45-49 years still show a high rate of acute HBV infection[163].

**LATIN AMERICA (epidemiology, molecular biology, prevention)**

***Epidemiology***

The information on the HBV epidemiology in Latin American countries is scanty and fragmentary, but it has been estimated that 7-12 million Latin Americans carry HBV chronic infection[164,165]. The rate of HBsAg-positive subjects varies between countries (Table 4)[166], the highest values being detected in the 20-40 age class as a possible consequence of a major role played by horizontal transmission[163].

More recently, some tropical Latin American areas such as Panama, Colombia and Venezuela shifted from an intermediate to a low endemicity level[166-169]. In addition, countries with a low HBV endemicity show a high rate of anti-HBc positivity in HBsAg-negative subjects, a clue to the more extensive exposure to HBV in the past[170,171]. A slight decline in the HBsAg-positive prevalence was observed from 1990 to 2005 in Andean Latin American countries, whereas a slight increase was reported in southern Latin America in the same period [16].

***Molecular epidemiology***

HBV genotypes F and H predominate in indigenous populations of Latin America, whereas genotypes A and D have been introduced from European and African populations[172,173]. Four subgenotypes of HBV genotype F (F1-F4) have been identified, predominating in Central America and frequent in Amerindians in all countries of South America[174-176] (Table 4), and HBV genotype H in Amerindians and in Mestizos in Mexico[177,178]. Genotypes F and H show a close phylogenetic relationship, suggesting an introduction of F/H ancestral strains before European colonization[174].

Introduced by European colonization, HBV genotypes D and A have been detected in nearly 35% and 5% of HBsAg-positive subjects of the urban population of Guadalajara and Jalisco (Mexico), respectively, while in various cities of Argentina they have been documented with frequencies ranging from 22% and 45%, respectively [177-179].

Genotypes B and C, introduced by Asian immigrants, are sporadically detected [180,181].

Worthy of note is that liver cirrhosis and hepatocellular carcinoma are rare in Mexicans, indicating that the immune response and course of liver disease in the Mexican native population may differ from that described in other geographical areas worldwide[182,183].

***Prevention***

Unfortunately, the universal vaccination programs remain unaffordable for most South American countries[184,185]. Where applied, however, they have achieved important epidemiological results, *e.g.*, in the Colombian Amazon, where the rate of HBsAg positivity dropped from 9% to 2% in children after eight years of application[186].

**FINAL COMMENTS**

Although of reduced impact in several countries due to the HBV universal vaccination programs started in the nineties’, HBV infection still entails a heavy socio-economic burden in several developing countries.

Vaccination programs should be extended without delay to cover rural areas of the countries where HBV vaccination is showing its efficacy in reducing the spread of HBV infection. Countries still unable to adopt a universal immunization program for newborn babies should receive support from international health organizations to implement this.

At present, the high cost of effective nucleo(t)side analogues, namely entecavir and tenofovir, to treat HBV infection and its correlated diseases is a strong handicap for most developing countries where numerous patients await treatment.

In addition, the information on the HBV epidemiology is scanty in several low-income countries and needs to be extended to cover information on HBV replication, co-infection with HCV and HIV, molecular epidemiology, phylogenies and clinical aspects.

In Africa, co-infection with HIV is a further problem that requires a therapeutic approach with the most appropriate combination therapies.

In Asia, a high viral load and a high prevalence of HBeAg-positive patients characterize HBV infection, and make the achievement of viral suppression more complex.

In Eastern Europe and South America, more epidemiological, virological and phylogenetic information is needed and further implementation of the vaccination programs to cover all the rural territories.

**References**

1 **WHO**. Hepatitis B. Available from: URL: http: //www.who.int/mediacentre/factsheets/fs204/en/

2 **Kramvis A**, Kew MC. Epidemiology of hepatitis B virus in Africa, its genotypes and clinical associations of genotypes. *Hepatol Res* 2007; **37**: S9-S19 [PMID: 17627641 DOI: 10.1111/j.1872-034X.2007.00098.x]

3 **WHO**. Relevè Epidemiologique hebdomadair. 2002. Available from: URL: http://www.who.int/wer/fr/

4 **Tao I**, Compaoré TR, Diarra B, Djigma F, Zohoncon TM, Assih M, Ouermi D, Pietra V, Karou SD, Simpore J. Seroepidemiology of hepatitis B and C viruses in the general population of burkina faso. *Hepat Res Treat* 2014; **2014**: 781843 [PMID: 25161770 DOI: 10.1155/2014/781843]

5 **Pietra V**, Kiema D, Sorgho D. Prevalence of Hepatitis B virus markers and hepatitis C virus antibodies in health staff in the District of Nanoro, Burkina Faso. Science and Technology, Science Sant´e, vol. 31, no. 1-2, 2008

6 **Collenberg E**, Ouedraogo T, Ganamé J, Fickenscher H, Kynast-Wolf G, Becher H, Kouyaté B, Kräusslich HG, Sangaré L, Tebit DM. Seroprevalence of six different viruses among pregnant women and blood donors in rural and urban Burkina Faso: A comparative analysis. *J Med Virol* 2006; **78**: 683-692 [PMID: 16555290 DOI: 10.1002/jmv.20593]

7 **Simpore J**, Granato M, Santarelli R, Nsme RA, Coluzzi M, Pietra V, Pignatelli S, Bere A, Faggioni A, Angeloni A. Prevalence of infection by HHV-8, HIV, HCV and HBV among pregnant women in Burkina Faso. *J Clin Virol* 2004; **31**: 78-80 [PMID: 15288619 DOI: 10.1016/j.jcv.2004.06.001]

8 **Belo AC**. Prevalence of hepatitis B virus markers in surgeons in Lagos, Nigeria. *East Afr Med J* 2000; **77**: 283-285 [PMID: 12858922]

9 **Bada AS**, Olatunji PO, Adewuyi JO, Iseniyi JO, Onile BA. Hepatitis B surface antigenaemia in Ilorin, Kwara State, Nigeria. *Cent Afr J Med* 1996; **42**: 139-141 [PMID: 8771932]

10 **Sadoh AE**, Sadoh WE. Serological markers of hepatitis B infection in infants presenting for their first immunization. *Niger J Paeadiatr* 2013; **40**: 248‑253 [DOI: 10.4314/njp.v40i3.9]

11 **Fouelifack Ymele F**, Keugoung B, Fouedjio JH, Kouam N, Mendibi S, Dongtsa Mabou J. High Rates of Hepatitis B and C and HIV Infections among Blood Donors in Cameroon: A Proposed Blood Screening Algorithm for Blood Donors in Resource-Limited Settings. *J Blood Transfus* 2012; **2012**: 458372 [PMID: 24066258 DOI: 10.1155/2012/458372]

12 **Noubiap JJ**, Joko WY, Nansseu JR, Tene UG, Siaka C. Sero-epidemiology of human immunodeficiency virus, hepatitis B and C viruses, and syphilis infections among first-time blood donors in Edéa, Cameroon. *Int J Infect Dis* 2013; **17**: e832-e837 [PMID: 23317526 DOI: 10.1016/j.ijid.2012.12.007]

13 **Euler GL**, Wooten KG, Baughman AL, Williams WW. Hepatitis B surface antigen prevalence among pregnant women in urban areas: implications for testing, reporting, and preventing perinatal transmission. *Pediatrics* 2003; **111**: 1192-1197 [PMID: 12728137]

14 **Njouom R**, Pasquier C, Ayouba A, Tejiokem MC, Vessiere A, Mfoupouendoun J, Tene G, Eteki N, Lobe MM, Izopet J, Nerrienet E. Low risk of mother-to-child transmission of hepatitis C virus in Yaounde, Cameroon: the ANRS 1262 study. *Am J Trop Med Hyg* 2005; **73**: 460-466 [PMID: 16103623]

15 **Fomulu NJ**, Morfaw FL, Torimiro JN, Nana P, Koh MV, William T. Prevalence, correlates and pattern of Hepatitis B among antenatal clinic attenders in Yaounde-Cameroon: is perinatal transmission of HBV neglected in Cameroon? *BMC Pregnancy Childbirth* 2013; **13**: 158 [PMID: 23924215 DOI: 10.1186/1471-2393-13-158]

16 **Ott JJ**, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. *Vaccine* 2012; **30**: 2212-2219 [PMID: 22273662 DOI: 10.1016/j.vaccine.2011.12.116]

17 **Komas NP**, Vickos U, Hübschen JM, Béré A, Manirakiza A, Muller CP, Le Faou A. Cross-sectional study of hepatitis B virus infection in rural communities, Central African Republic. *BMC Infect Dis* 2013; **13**: 286 [PMID: 23800310 DOI: 10.1186/1471-2334-13-286]

18 **Peto TJ**, Mendy ME, Lowe Y, Webb EL, Whittle HC, Hall AJ. Efficacy and effectiveness of infant vaccination against chronic hepatitis B in the Gambia Hepatitis Intervention Study (1986-90) and in the nationwide immunisation program. *BMC Infect Dis* 2014; **14**: 7 [PMID: 24397793 DOI: 10.1186/1471-2334-14-7]

19 **Bovet P**, Yersin C, Herminie P, Lavanchy D, Frei PC. Decrease in the prevalence of hepatitis B and a low prevalence of hepatitis C virus infections in the general population of the Seychelles. *Bull World Health Organ* 1999; **77**: 923-928 [PMID: 10612888]

20 **Chiaramonte M**, Stroffolini T, Ngatchu T, Rapicetta M, Lantum D, Kaptue L, Chionne P, Conti S, Sarrecchia B, Naccarato R. Hepatitis B virus infection in Cameroon: a seroepidemiological survey in city school children. *J Med Virol* 1991; **33**: 95-99 [PMID: 2051143]

21 **Sirisena ND**, Njoku MO, Idoko JA, Isamade E, Barau C, Jelpe D, Zamani A, Otowo S. Carriage rate of hepatitis-B surface antigen (HBsAg) in an urban community in Jos, Plateau State, Nigeria. *Niger Postgrad Med J* 2002; **9**: 7-10 [PMID: 11932753]

22 **Jacobs B**, Mayaud P, Changalucha J, Todd J, Ka-Gina G, Grosskurth H, Berege ZA. Sexual transmission of hepatitis B in Mwanza, Tanzania. *Sex Transm Dis* 1997; **24**: 121-126 [PMID: 9132977]

23 **Bile K**, Mohamud O, Aden C, Isse A, Norder H, Nilsson L, Magnius L. The risk for hepatitis A, B, and C at two institutions for children in Somalia with different socioeconomic conditions. *Am J Trop Med Hyg* 1992; **47**: 357-364 [PMID: 1524149]

24 **Tswana SA**, Moyo SR. The interrelationship between HBV-markers and HIV antibodies in patients with hepatocellular carcinoma. *J Med Virol* 1992; **37**: 161-164 [PMID: 1279108]

25 **Abiodun PO**, Olomu A, Okolo SN, Obasohan A, Freeman O. The prevalence of hepatitis Be antigen and anti-HBE in adults in Benin City. *West Afr J Med* 1994; **13**: 171-174 [PMID: 7841109]

26 **Hodges M**, Sanders E, Aitken C. Seroprevalence of hepatitis markers; HAV, HBV, HCV and HEV amongst primary school children in Freetown, Sierra Leone. *West Afr J Med* 1998; **17**: 36-37 [PMID: 9643158]

27 **Abebe A**, Nokes DJ, Dejene A, Enquselassie F, Messele T, Cutts FT. Seroepidemiology of hepatitis B virus in Addis Ababa, Ethiopia: transmission patterns and vaccine control. *Epidemiol Infect* 2003; **131**: 757-770 [PMID: 12948377]

28 **Odaibo GN**, Arotiba JT, Fasola AO, Obiechina AE, Olaleye OD, Ajagbe HA. Prevalence of hepatitis B virus surface antigen (HBsAg) in patients undergoing extraction at the University College Hospital, Ibadan. *Afr J Med Med Sci* 2003; **32**: 243-245 [PMID: 15030081]

29 **Jombo GT**, Egah DZ, Banwat EB. Hepatitis B virus infection in a rural settlement of northern Nigeria. *Niger J Med* 2005; **14**: 425-428 [PMID: 16353707]

30 **Uneke CJ**, Ogbu O, Inyama PU, Anyanwu GI, Njoku MO, Idoko JH. Prevalence of hepatitis-B surface antigen among blood donors and human immunodeficiency virus-infected patients in Jos, Nigeria. *Mem Inst Oswaldo Cruz* 2005; **100**: 13-16 [PMID: 15867956]

31 **Kirk GD**, Bah E, Montesano R. Molecular epidemiology of human liver cancer: insights into etiology, pathogenesis and prevention from The Gambia, West Africa. *Carcinogenesis* 2006; **27**: 2070-2082 [PMID: 16679307 DOI: 10.1093/carcin/bgl060]

32 **Heikel J**, Sekkat S, Bouqdir F, Rich H, Takourt B, Radouani F, Hda N, Ibrahimy S, Benslimane A. The prevalence of sexually transmitted pathogens in patients presenting to a Casablanca STD clinic. *Eur J Epidemiol* 1999; **15**: 711-715 [PMID: 10555614]

33 **Iorio R**, Giannattasio A, Cirillo F, D' Alessandro L, Vegnente A. Long-term outcome in children with chronic hepatitis B: a 24-year observation period. *Clin Infect Dis* 2007; **45**: 943-949 [PMID: 17879906 DOI: 10.1086/521864]

34 **Hadziyannis SJ**. Hepatitis B e antigen negative chronic hepatitis B: from clinical recognition to pathogenesis and treatment. *Viral Hepat Rev* 1995; **1**: 7–36

35 **Hadziyannis SJ**, Vassilopoulos D. Hepatitis B e antigen-negative chronic hepatitis B. *Hepatology* 2001; **34**: 617-624 [PMID: 11584355 DOI: 10.1053/jhep.2001.27834]

36 **Acquaye JK**, Mingle JA. Hepatitis B viral markers in Ghanaian pregnant women. *West Afr J Med* 1994; **13**: 134-137 [PMID: 7841099]

37 **Harry TO**, Bajani MD, Moses AE. Hepatitis B virus infection among blood donors and pregnant women in Maiduguri, Nigeria. *East Afr Med J* 1994; **71**: 596-597 [PMID: 7875094]

38 **Madzime S**, Adem M, Mahomed K, Woelk GB, Mudzamiri S, Williams MA. Hepatitis B virus infection among pregnant women delivering at Harare Maternity Hospital, Harare Zimbabwe, 1996 to 1997. *Cent Afr J Med* 1999; **45**: 195-198 [PMID: 10697914]

39 **Guidozzi F**, Schoub BD, Johnson S, Song E. Should pregnant urban south African women be screened for hepatitis B? *S Afr Med J* 1993; **83**: 103-105 [PMID: 8451683]

40 **Roingeard P**, Diouf A, Sankale JL, Boye C, Mboup S, Diadhiou F, Essex M. Perinatal transmission of hepatitis B virus in Senegal, west Africa. *Viral Immunol* 1993; **6**: 65-73 [PMID: 8476509]

41 **Oshitani H**, Kasolo F, Tembo C, Mpabalwani M, Mizuta K, Luo N, Suzuki H, Numazaki Y. Hepatitis B virus infection among pregnant women in Zambia. *East Afr Med J* 1995; **72**: 813-815 [PMID: 8689985]

42 **Menendez C**, Sanchez-Tapias JM, Kahigwa E, Mshinda H, Costa J, Vidal J, Acosta C, Lopez-Labrador X, Olmedo E, Navia M, Tanner M, Rodes J, Alonso PL. Prevalence and mother-to-infant transmission of hepatitis viruses B, C, and E in Southern Tanzania. *J Med Virol* 1999; **58**: 215-220 [PMID: 10447415 DOI: 10.1002/(SICI)1096-9071(199907)58:3<215::AID-JMV5>3.0.CO;2-K]

43 **Kiire CF**. The epidemiology and prophylaxis of hepatitis B in sub-Saharan Africa: a view from tropical and subtropical Africa. *Gut* 1996; **38** Suppl 2: S5-12 [PMID: 8786055]

44 **Barth RE**, Huijgen Q, Taljaard J, Hoepelman AI. Hepatitis B/C and HIV in sub-Saharan Africa: an association between highly prevalent infectious diseases. A systematic review and meta-analysis. *Int J Infect Dis* 2010; **14**: e1024-e1031 [PMID: 20870439 DOI: 10.1016/j.ijid.2010.06.013]

45 **Day SL**, Odem-Davis K, Mandaliya KN, Jerome KR, Cook L, Masese LN, Scott J, Kim HN, Graham SM, McClelland RS. Prevalence, clinical and virologic outcomes of hepatitis B virus co-infection in HIV-1 positive Kenyan women on antiretroviral therapy. *PLoS One* 2013; **8**: e59346 [PMID: 23527168 DOI: 10.1371/journal.pone.0059346]

46 **Ayuk J**, Mphahlele J, Bessong P. Hepatitis B virus in HIV-infected patients in northeastern South Africa: prevalence, exposure, protection and response to HAART. *S Afr Med J* 2013; **103**: 330-333 [PMID: 23971125]

47 **Ladep NG**, Agaba PA, Agbaji O, Muazu A, Ugoagwu P, Imade G, Cooke G, McCormack S, Taylor-Robinson SD, Idoko J, Kanki P. Rates and impact of hepatitis on human immunodeficiency virus infection in a large African cohort. *World J Gastroenterol* 2013; **19**: 1602-1610 [PMID: 23538773 DOI: 10.3748/wjg.v19.i10.1602]

48 **Mayaphi SH**, Roussow TM, Masemola DP, Olorunju SA, Mphahlele MJ, Martin DJ. HBV/HIV co-infection: the dynamics of HBV in South African patients with AIDS. *S Afr Med J* 2012; **102**: 157-162 [PMID: 22380911]

49 **Franzeck FC**, Ngwale R, Msongole B, Hamisi M, Abdul O, Henning L, Letang E, Mwaigomole G, Battegay M, Hatz C, Tanner M. Viral hepatitis and rapid diagnostic test based screening for HBsAg in HIV-infected patients in rural Tanzania. *PLoS One* 2013; **8**: e58468 [PMID: 23469281 DOI: 10.1371/journal.pone.0058468]

50 **Stabinski L**, OʼConnor S, Barnhart M, Kahn RJ, Hamm TE. Prevalence of HIV and hepatitis B virus co-infection in sub-Saharan Africa and the potential impact and program feasibility of hepatitis B surface antigen screening in resource-limited settings. *J Acquir Immune Defic Syndr* 2015; **68** Suppl 3: S274-S285 [PMID: 25768867 DOI: 10.1097/QAI.0000000000000496]

51 **Garrido C**, Trevino A, Bautista J. High rate of chronic hepatitis B, overt and occult, in a virological survey of hepatitis viruses and human retroviruses in Ghana. *Antivir Ther* 2011; **15**: 1029–1034

52 **N'Dri-Yoman T**, Anglaret X, Messou E, Attia A, Polneau S, Toni T, Chenal H, Seyler C, Gabillard D, Wakasugi N, Eholié S, Danel C. Occult HBV infection in untreated HIV-infected adults in Côte d'Ivoire. *Antivir Ther* 2010; **15**: 1029-1034 [PMID: 21041918 DOI: 10.3851/IMP1641]

53 **Araujo NM**, Branco-Vieira M, Silva AC, Pilotto JH, Grinsztejn B, de Almeida AJ, Trepo C, Gomes SA. Occult hepatitis B virus infection in HIV-infected patients: Evaluation of biochemical, virological and molecular parameters. *Hepatol Res* 2008; **38**: 1194-1203 [PMID: 18624719 DOI: 10.1111/j.1872-034X.2008.00392.x]

54 **Barth RE**, Huijgen Q, Tempelman HA, Mudrikova T, Wensing AM, Hoepelman AI. Presence of occult HBV, but near absence of active HBV and HCV infections in people infected with HIV in rural South Africa. *J Med Virol* 2011; **83**: 929-934 [PMID: 21503902 DOI: 10.1002/jmv.22026]

55 **Mphahlele MJ**, Lukhwareni A, Burnett RJ, Moropeng LM, Ngobeni JM. High risk of occult hepatitis B virus infection in HIV-positive patients from South Africa. *J Clin Virol* 2006; **35**: 14-20 [PMID: 15916918 DOI: 10.1016/j.jcv.2005.04.003]

56 **Bell TG**, Makondo E, Martinson NA, Kramvis A. Hepatitis B virus infection in human immunodeficiency virus infected southern African adults: occult or overt--that is the question. *PLoS One* 2012; **7**: e45750 [PMID: 23049685 DOI: 10.1371/journal.pone.0045750]

57 **Vardas E**, Mathai M, Blaauw D, McAnerney J, Coppin A, Sim J. Preimmunization epidemiology of hepatitis B virus infection in South African children. *J Med Virol* 1999; **58**: 111-115 [PMID: 10335856 DOI: 10.1002/(SICI)1096-9071(199906)58: 2<111: : AID-JMV2>3.0.CO; 2-B]

58 **Ugwuja EI**, Ugwu NC. Seroprevalence of hepatitis B surface antigen and liver function tests among adolescents in Abakaliki, South Eastern Nigeria. *Internet J Tropical Med* 2010; **6**: 2

59 **Dumpis U**, Holmes EC, Mendy M, Hill A, Thursz M, Hall A, Whittle H, Karayiannis P. Transmission of hepatitis B virus infection in Gambian families revealed by phylogenetic analysis. *J Hepatol* 2001; **35**: 99-104 [PMID: 11495049 DOI: 10.1016/S0168-8278(01)00064-2]

60 **Otegbayo JA**, Fasola FA, Abja A. Prevalence of hepatitis B surface and e antigens, risk factors for viral acquisition and serum transaminase among blood donors in Ibadan, Nigeria. *Trop Gastroenterol* 2003; **24**: 196-197 [PMID: 15164531]

61 **McCarthy MC**, el-Tigani A, Khalid IO, Hyams KC. Hepatitis B and C in Juba, southern Sudan: results of a serosurvey. *Trans R Soc Trop Med Hyg* 1994; **88**: 534-536 [PMID: 7992329]

62 **Sidibe S**, Sacko BY, Traoré I. [Prevalence of serologic markers of the hepatitis B virus in pregnant women of Bamako, Mali]. *Bull Soc Pathol Exot* 2001; **94**: 339-341 [PMID: 11845531]

63 **Pido B**, Kagimu M. Prevalence of hepatitis B virus (HBV) infection among Makerere University medical students. *Afr Health Sci* 2005; **5**: 93-98 [PMID: 16006214]

64 **World Health Organization**. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. Geneva, Switzerland: World Health Organization; 2011. Available from: URL: http: //www.who.int/ vmnis/indicators/haemoglobin.pdf

65 **Apata IW**, Averhoff F, Pitman J, Bjork A, Yu J, Amin NA, Dhingra N, Kolwaite A, Marfin A; Centers for Disease Control and Prevention (CDC). Progress toward prevention of transfusion-transmitted hepatitis B and hepatitis C infection--sub-Saharan Africa, 2000-2011. *MMWR Morb Mortal Wkly Rep* 2014; **63**: 613-619 [PMID: 25055184]

66 **Kurbanov F**, Tanaka Y, Fujiwara K, Sugauchi F, Mbanya D, Zekeng L, Ndembi N, Ngansop C, Kaptue L, Miura T, Ido E, Hayami M, Ichimura H, Mizokami M. A new subtype (subgenotype) Ac (A3) of hepatitis B virus and recombination between genotypes A and E in Cameroon. *J Gen Virol* 2005; **86**: 2047-2056 [PMID: 15958684 DOI: 10.1099/vir.0.80922-0]

67 **Olinger CM**, Venard V, Njayou M, Oyefolu AO, Maïga I, Kemp AJ, Omilabu SA, le Faou A, Muller CP. Phylogenetic analysis of the precore/core gene of hepatitis B virus genotypes E and A in West Africa: new subtypes, mixed infections and recombinations. *J Gen Virol* 2006; **87**: 1163-1173 [PMID: 16603517 DOI: 10.1099/vir.0.81614-0]

68 **Owiredu WK**, Kramvis A, Kew MC. Hepatitis B virus DNA in serum of healthy black African adults positive for hepatitis B surface antibody alone: possible association with recombination between genotypes A and D. *J Med Virol* 2001; **64**: 441-454 [PMID: 11468728 DOI: 10.1002/jmv.1070]

69 **Norder H**, Couroucé AM, Coursaget P, Echevarria JM, Lee SD, Mushahwar IK, Robertson BH, Locarnini S, Magnius LO. Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes. *Intervirology* 2004; **47**: 289-309 [PMID: 15564741 DOI: 10.1159/000080872]

70 **Bowyer SM**, van Staden L, Kew MC, Sim JG. A unique segment of the hepatitis B virus group A genotype identified in isolates from South Africa. *J Gen Virol* 1997; **78 ( Pt 7)**: 1719-1729 [PMID: 9225049]

71 **Kramvis A**, Weitzmann L, Owiredu WK, Kew MC. Analysis of the complete genome of subgroup A' hepatitis B virus isolates from South Africa. *J Gen Virol* 2002; **83**: 835-839 [PMID: 11907333]

72 **Sugauchi F**, Kumada H, Acharya SA, Shrestha SM, Gamutan MT, Khan M, Gish RG, Tanaka Y, Kato T, Orito E, Ueda R, Miyakawa Y, Mizokami M. Epidemiological and sequence differences between two subtypes (Ae and Aa) of hepatitis B virus genotype A. *J Gen Virol* 2004; **85**: 811-820 [PMID: 15039524 DOI: 10.1099/vir.0.79811-0]

73 **Hannoun C**, Söderström A, Norkrans G, Lindh M. Phylogeny of African complete genomes reveals a West African genotype A subtype of hepatitis B virus and relatedness between Somali and Asian A1 sequences. *J Gen Virol* 2005; **86**: 2163-2167 [PMID: 16033963 DOI: 10.1099/vir.0.80972-0]

74 **Mulders MN**, Venard V, Njayou M, Edorh AP, Bola Oyefolu AO, Kehinde MO, Muyembe Tamfum JJ, Nebie YK, Maiga I, Ammerlaan W, Fack F, Omilabu SA, Le Faou A, Muller CP. Low genetic diversity despite hyperendemicity of hepatitis B virus genotype E throughout West Africa. *J Infect Dis* 2004; **190**: 400-408 [PMID: 15216479 DOI: 10.1086/421502]

75 **Bozdayi G**, Türkyilmaz AR, Idilman R, Karatayli E, Rota S, Yurdaydin C, Bozdayi AM. Complete genome sequence and phylogenetic analysis of hepatitis B virus isolated from Turkish patients with chronic HBV infection. *J Med Virol* 2005; **76**: 476-481 [PMID: 15977237 DOI: 10.1002/jmv.20386]

76 **Cox LE**, Arslan O, Allain JP. Characterization of hepatitis B virus in Turkish blood donors, and the prevalence of the SP1 splice variant. *J Med Virol* 2011; **83**: 1321-1325 [PMID: 21678435 DOI: 10.1002/jmv.22118]

77 **Kitab B**, El Feydi AE, Afifi R, Derdabi O, Cherradi Y, Benazzouz M, Rebbani K, Brahim I, Salih Alj H, Zoulim F, Trepo C, Chemin I, Ezzikouri S, Benjelloun S. Hepatitis B genotypes/subgenotypes and MHR variants among Moroccan chronic carriers. *J Infect* 2011; **63**: 66-75 [PMID: 21640384 DOI: 10.1016/j.jinf.2011.05.007]

78 **Zehender G**, Ebranati E, Gabanelli E, Shkjezi R, Lai A, Sorrentino C, Lo Presti A, Basho M, Bruno R, Tanzi E, Bino S, Ciccozzi M, Galli M. Spatial and temporal dynamics of hepatitis B virus D genotype in Europe and the Mediterranean Basin. *PLoS One* 2012; **7**: e37198 [PMID: 22662136 DOI: 10.1371/journal.pone.0037198]

79 **Zehender G**, Shkjezi R, Ebranati E, Gabanelli E, Abazaj Z, Tanzi E, Kraja D, Bino S, Ciccozzi M, Galli M. Reconstruction of the epidemic history of hepatitis B virus genotype D in Albania. *Infect Genet Evol* 2012; **12**: 291-298 [PMID: 22142487 DOI: 10.1016/j.meegid.2011.11.009]

80 **Burnett RJ**, Kramvis A, Dochez C, Meheus A. An update after 16 years of hepatitis B vaccination in South Africa. *Vaccine* 2012; **30** Suppl 3: C45-C51 [PMID: 22939021 DOI: 10.1016/j.vaccine.2012.02.021]

81 **Irungu E**, Mugo N, Ngure K, Njuguna R, Celum C, Farquhar C, Dhanireddy S, Baeten JM. Immune response to hepatitis B virus vaccination among HIV-1 infected and uninfected adults in Kenya. *J Infect Dis* 2013; **207**: 402-410 [PMID: 23175769 DOI: 10.1093/infdis/jis695]

82 **Elbadawi IA**. Reviving growth in the Arab world. *Econ Dev Cult Change* 2005; **53**: 293–326 [DOI: 10.1086/425375]

83 **Centers for Disease Control and Prevention**. Health Information for International Travel 2016: The Yellow Book. Chapter 3 - Infectious Diseases Related to Travel. Available from: URL: http://wwwnc.cdc.gov/travel/yellowbook/2016/infectious-diseases-related-to-travel/b-virus

84 **Culcasi K**. Constructing and naturalizing the Middle East. *Geogr Rev* 2010; **100**: 583–597 [DOI: 10.1111/j.1931-0846.2010.00059.x]

85 **Memish ZA**, Knawy BA, El-Saed A. Incidence trends of viral hepatitis A, B, and C seropositivity over eight years of surveillance in Saudi Arabia. *Int J Infect Dis* 2010; **14**: e115-e120 [PMID: 19540786 DOI: 10.1016/j.ijid.2009.03.027]

86 **Lavanchy D**. Chronic viral hepatitis as a public health issue in the world. *Best Pract Res Clin Gastroenterol* 2008; **22**: 991-1008 [PMID: 19187863 DOI: 10.1016/j.bpg.2008.11.002]

87 **Al-Waleedi AA**, Khader YS. Prevalence of hepatitis B and C infections and associated factors among blood donors in Aden City, Yemen. *East Mediterr Health J* 2012; **18**: 624-629 [PMID: 22888620]

88 **Ameen R**, Sanad N, Al-Shemmari S, Siddique I, Chowdhury RI, Al-Hamdan S, Al-Bashir A. Prevalence of viral markers among first-time Arab blood donors in Kuwait. *Transfusion* 2005; **45**: 1973-1980 [PMID: 16371052 DOI: 10.1111/j.1537-2995.2005.00635.x]

89 **Ataallah TM**, Hanan KA, Maysoun KS, Sadoon AA. Prevalence of hepatitis B and C among blood donors attending the National Blood Transfusion Center in Baghdad, Iraq from 2006-2009. *Saudi Med J* 2011; **32**: 1046-1050 [PMID: 22008925]

90 **Saab BR**, Nassar NT, Musharrafieh U, Araj GF, Khogali M. Prevalence of hepatitis B in a presumably healthy Lebanese population. *J Med Liban* 2007; **55**: 11-14 [PMID: 17489302]

91 **Al-Gani FA**. Prevalence of HBV, HCV and HIV-1, 2 infections among blood donors in Prince Rashed Ben Al-Hassan hospital in North region of Jordan. *Int J Biol Med Res* 2011; **2**: 912–916

92 **Yassin K**, Awad R, Tebi AJ, Queder A, Laaser U. Prevalence and risk factors of HBsAg in Gaza: implications for prevention and control. *J Infect* 2002; **44**: 252-256 [PMID: 12099733]

93 **Specialist Panel on Chronic Hepatitis B in the Middle East.** A review of chronic hepatitis B epidemiology and management issues in selected countries in the Middle East. *J Viral Hepat* 2012; **19**: 9-22 [PMID: 22187943 DOI: 10.1111/j.1365-2893.2011.01511.x]

94 **Al-Faleh FZ**, Al-Jeffri M, Ramia S, Al-Rashed R, Arif M, Rezeig M, Al-Toraif I, Bakhsh M, Mishkkhas A, Makki O, Al-Freihi H, Mirdad S, AlJuma A, Yasin T, Al-Swailem A, Ayoola A. Seroepidemiology of hepatitis B virus infection in Saudi children 8 years after a mass hepatitis B vaccination programme. *J Infect* 1999; **38**: 167-170 [PMID: 10424796 DOI: 10.1016/0163-4453(92)93006-C]

95 **Alfaleh F**, Alshehri S, Alansari S, Aljeffri M, Almazrou Y, Shaffi A, Abdo AA. Long-term protection of hepatitis B vaccine 18 years after vaccination. *J Infect* 2008; **57**: 404-409 [PMID: 18829116 DOI: 10.1016/j.jinf.2008.08.008]

96 **Yamada H**, Fujimoto M, Svay S, Lim O, Hok S, Goto N, Ohisa M, Akita T, Matsuo J, Do SH, Katayama K, Miyakawa Y, Tanaka J. Seroprevalence, genotypic distribution and potential risk factors of hepatitis B and C virus infections among adults in Siem Reap, Cambodia. *Hepatol Res* 2015; **45**: 480-487 [PMID: 24905888 DOI: 10.1111/hepr.12367]

97 **Ol HS**, Bjoerkvoll B, Sothy S, Van Heng Y, Hoel H, Husebekk A, Gutteberg T, Larsen S, Husum H. Prevalence of hepatitis B and hepatitis C virus infections in potential blood donors in rural Cambodia. *Southeast Asian J Trop Med Public Health* 2009; **40**: 963-971 [PMID: 19842380]

98 **Caruana SR**, Kelly HA, De Silva SL, Chea L, Nuon S, Saykao P, Bak N, Biggs BA. Knowledge about hepatitis and previous exposure to hepatitis viruses in immigrants and refugees from the Mekong Region. *Aust N Z J Public Health* 2005; **29**: 64-68 [PMID: 15782875 DOI: 10.1111/j.1467-842X.2005.tb00751.x]

99 **Ang LW**, Cutter J, James L, Goh KT. Seroepidemiology of hepatitis B virus infection among adults in Singapore: a 12-year review. *Vaccine* 2013; **32**: 103-110 [PMID: 24200974 DOI: 10.1016/j.vaccine.2013.10.057]

100 **Luo Z**, Li L, Ruan B. Impact of the implementation of a vaccination strategy on hepatitis B virus infections in China over a 20-year period. *Int J Infect Dis* 2012; **16**: e82-e88 [PMID: 22178658 DOI: 10.1016/j.ijid.2011.10.009]

101 **Cui F**, Li L, Hadler SC, Wang F, Zheng H, Chen Y, Gong X, Hutin YJ, Cairns KL, Liang X, Yang W. Factors associated with effectiveness of the first dose of hepatitis B vaccine in China: 1992-2005. *Vaccine* 2010; **28**: 5973-5978 [PMID: 20637773 DOI: 10.1016/j.vaccine.2010.06.111]

102 **Liang X**, Bi S, Yang W, Wang L, Cui G, Cui F, Zhang Y, Liu J, Gong X, Chen Y, Wang F, Zheng H, Wang F, Guo J, Jia Z, Ma J, Wang H, Luo H, Li L, Jin S, Hadler SC, Wang Y. Epidemiological serosurvey of hepatitis B in China--declining HBV prevalence due to hepatitis B vaccination. *Vaccine* 2009; **27**: 6550-6557 [PMID: 19729084 DOI: 10.1016/j.vaccine.2009.08.048]

103 **Wang C**, Sun J, Zhu B, Larsen S, Yu R, Wu J, Zhao W. Hepatitis B virus infection and related factors in hemodialysis patients in China - systematic review and meta-analysis. *Ren Fail* 2010; **32**: 1255-1264 [PMID: 20954991 DOI: 10.3109/0886022X.2010.517354]

104 **Yan YX**, Gao YQ, Sun X, Wang W, Huang XJ, Zhang T, Li M, Zang CP, Li ZC, Wu H. Prevalence of hepatitis C virus and hepatitis B virus infections in HIV-positive Chinese patients. *Epidemiol Infect* 2011; **139**: 354-360 [PMID: 20598209 DOI: 10.1017/S0950268810001597]

105 **Lee BS**, Cho YK, Jeong SH, Lee JH, Lee D, Park NH, Ki M; Korean Hepatitis Epidemiology Study Group. Nationwide seroepidemiology of hepatitis B virus infection in South Korea in 2009 emphasizes the coexistence of HBsAg and anti-HBs. *J Med Virol* 2013; **85**: 1327-1333 [PMID: 23723057 DOI: 10.1002/jmv.23594]

106 **Kim H**, Shin AR, Chung HH, Kim MK, Lee JS, Shim JJ, Kim BH. Recent trends in hepatitis B virus infection in the general Korean population. *Korean J Intern Med* 2013; **28**: 413-419 [PMID: 23864799 DOI: 10.3904/kjim.2013.28.4.413]

107 **Nurgalieva ZZ**, Hollinger FB, Graham DY, Zhangabylova S, Zhangabylov A. Epidemiology and transmission of hepatitis B and C viruses in Kazakhstan. *World J Gastroenterol* 2007; **13**: 1204-1207 [PMID: 17451200 DOI: 10.3748/wjg.v13.i8.1204]

108 **Batham A**, Gupta MA, Rastogi P, Garg S, Sreenivas V, Puliyel JM. Calculating prevalence of hepatitis B in India: using population weights to look for publication bias in conventional meta-analysis. *Indian J Pediatr* 2009; **76**: 1247-1257 [PMID: 20108060 DOI: 10.1007/s12098-009-0246-3]

109 **Ozaras R**, Inanc Balkan I, Yemisen M, Tabak F. Epidemiology of HBV subgenotypes D. *Clin Res Hepatol Gastroenterol* 2015; **39**: 28-37 [PMID: 25037178 DOI: 10.1016/j.clinre.2014.06.005]

110 **Pourkarim MR**, Vergote V, Amini-Bavil-Olyaee S, Sharifi Z, Sijmons S, Lemey P, Maes P, Alavian SM, Van Ranst M. Molecular characterization of hepatitis B virus (HBV) strains circulating in the northern coast of the Persian Gulf and its comparison with worldwide distribution of HBV subgenotype D1. *J Med Virol* 2014; **86**: 745-757 [PMID: 24532489 DOI: 10.1002/jmv.23864]

111 **Xiang Y**, Huang S, Xia J, Ye D, Chen P, Zhang L. Characterization of hepatitis B virus molecular genotypes in Chongqing and quantitative serological markers in patients during natural phases of chronic hepatitis B infection. *Intervirology* 2012; **55**: 68-72 [PMID: 21293110 DOI: 10.1159/000323524]

112 **Li XD**, Wang L, Liu Y, Xu ZH, Dai JZ, Li L, Yao ZT, Xin SJ, Zhao JM, Xu DP. Characterization of hepatitis B virus genotypes/subgenotypes in 1,301 patients with chronic hepatitis B in North China. *Chin Med J (Engl)* 2011; **124**: 4178-4183 [PMID: 22340383]

113 **Wang HY**, Li D, Liu W, Jin X, Du B, Li YP, Gu HX, Zhang SY. Hepatitis B virus subgenotype C2 is the most prevalent subgenotype in northeast China. *Clin Microbiol Infect* 2010; **16**: 477-481 [PMID: 19456822 DOI: 10.1111/j.1469-0691.2009.02834.x]

114 **Yuan J**, Zhou B, Tanaka Y, Kurbanov F, Orito E, Gong Z, Xu L, Lu J, Jiang X, Lai W, Mizokami M. Hepatitis B virus (HBV) genotypes/subgenotypes in China: mutations in core promoter and precore/core and their clinical implications. *J Clin Virol* 2007; **39**: 87-93 [PMID: 17451999 DOI: 10.1016/j.jcv.2007.03.005]

115 **Wang Z**, Tanaka Y, Huang Y, Kurbanov F, Chen J, Zeng G, Zhou B, Mizokami M, Hou J. Clinical and virological characteristics of hepatitis B virus subgenotypes Ba, C1, and C2 in China. *J Clin Microbiol* 2007; **45**: 1491-1496 [PMID: 17376881 DOI: 10.1128/JCM.02157-06]

116 **You J**, Sriplung H, Chongsuvivatwong V, Geater A, Zhuang L, Huang JH, Chen HY, Yu L, Tang BZ. Profile, spectrum and significance of hepatitis B virus genotypes in chronic HBV-infected patients in Yunnan, China. *Hepatobiliary Pancreat Dis Int* 2008; **7**: 271-279 [PMID: 18522881]

117 **Zhu CT**, Dong CL. Characteristics of general distribution of hepatitis B virus genotypes in China. *Hepatobiliary Pancreat Dis Int* 2009; **8**: 397-401 [PMID: 19666409]

118 **Wang Z**, Hou J, Zeng G, Wen S, Tanaka Y, Cheng J, Kurbanov F, Wang L, Jiang J, Naoumov NV, Mizokami M, Qi Y. Distribution and characteristics of hepatitis B virus genotype C subgenotypes in China. *J Viral Hepat* 2007; **14**: 426-434 [PMID: 17501764 DOI: 10.1111/j.1365-2893.2006.00813.x]

119 **Wang B**, Feng Y, Li Z, Duan H, Zhao T, Zhang A, Liu L, Baloch Z, Xia X. Distribution and diversity of hepatitis B virus genotypes in Yunnan, China. *J Med Virol* 2014; **86**: 1675-1682 [PMID: 24992445 DOI: 10.1002/jmv.24002]

120 **Yin J**, Zhang H, He Y, Xie J, Liu S, Chang W, Tan X, Gu C, Lu W, Wang H, Bi S, Cui F, Liang X, Schaefer S, Cao G. Distribution and hepatocellular carcinoma-related viral properties of hepatitis B virus genotypes in Mainland China: a community-based study. *Cancer Epidemiol Biomarkers Prev* 2010; **19**: 777-786 [PMID: 20160279 DOI: 10.1158/1055-9965.EPI-09-1001]

121 **Mumtaz K**, Hamid S, Ahmed S, Moatter T, Mushtaq S, Khan A, Mizokami M, Jafri W. A study of genotypes, mutants and nucleotide sequence of hepatitis B virus in Pakistan: HBV genotypes in pakistan. *Hepat Mon* 2011; **11**: 14-18 [PMID: 22087110]

122 **Morozov V**, Pisareva M, Groudinin M. Homologous recombination between different genotypes of hepatitis B virus. *Gene* 2000; **260**: 55-65 [PMID: 11137291 DOI: 10.1016/S0378-1119(00)00424-8]

123 **Ghosh S**, Banerjee P, Deny P, Mondal RK, Nandi M, Roychoudhury A, Das K, Banerjee S, Santra A, Zoulim F, Chowdhury A, Datta S. New HBV subgenotype D9, a novel D/C recombinant, identified in patients with chronic HBeAg-negative infection in Eastern India. *J Viral Hepat* 2013; **20**: 209-218 [PMID: 23383660 DOI: 10.1111/j.1365-2893.2012.01655.x]

124 **Datta S**. An overview of molecular epidemiology of hepatitis B virus (HBV) in India. *Virol J* 2008; **5**: 156 [PMID: 19099581 DOI: 10.1186/1743-422X-5-156]

125 **Banerjee P**, Mondal RK, Nandi M, Ghosh S, Khatun M, Chakraborty N, Bhattacharya S, RoyChoudhury A, Banerjee S, Santra A, Sil S, Chowdhury A, Bhaumik P, Datta S. A rare HBV subgenotype D4 with unique genomic signatures identified in north-eastern India--an emerging clinical challenge? *PLoS One* 2014; **9**: e109425 [PMID: 25295865 DOI: 10.1371/journal.pone.0109425.eCollection 2014]

126 **Hennessey K**, Mendoza-Aldana J, Bayutas B, Lorenzo-Mariano KM, Diorditsa S. Hepatitis B control in the World Health Organization's Western Pacific Region: targets, strategies, status. *Vaccine* 2013; **31** Suppl 9: J85-J92 [PMID: 24331026 DOI: 10.1016/j.vaccine.2012.10.082]

127 **Kane MA**, Hadler SC, Lee L, Shapiro CN, Cui F, Wang X, Kumar R. The inception, achievements, and implications of the China GAVI Alliance Project on Hepatitis B Immunization. *Vaccine* 2013; **31** Suppl 9: J15-J20 [PMID: 24331015 DOI: 10.1016/j.vaccine.2013.03.045]

128 **Lazarevic I**, Cupic M, Delic D, Svirtlih NS, Simonovic J, Jovanovic T. Distribution of HBV genotypes, subgenotypes and HBsAg subtypes among chronically infected patients in Serbia. *Arch Virol* 2007; **152**: 2017-2025 [PMID: 17680327 DOI: 10.1007/s00705-007-1031-0]

129 **Lazarevic I**, Cupic M, Delic D, Svirtlih NS, Simonovic J, Jovanovic T. Prevalence of hepatitis B virus MHR mutations and their correlation with genotypes and antiviral therapy in chronically infected patients in Serbia. *J Med Virol* 2010; **82**: 1160-1167 [PMID: 20513079 DOI: 10.1002/jmv.21810]

130 **Liaw YF**, Brunetto MR, Hadziyannis S. The natural history of chronic HBV infection and geographical differences. *Antivir Ther* 2010; **15** Suppl 3: 25-33 [PMID: 21041901 DOI: 10.3851/IMP1621]

131 **Tekin Koruk S**, Koruk I, Gursoy B, Çalisir C, Kuksell F, Yildiz Zeyrek F. Hepatitis B and Hepatitis C Seroprevalence in the Center of Sanliurfa Province From Southeastern Anatolia Region and Related Risk Factors. *Balkan Med J* 2010; **27**: 367-372 [DOI: 10.5174/tutfd.2009.02533.0]

132 **Kevorkyan A**, Teoharov P, Lernout T, Petrova N, Raycheva R, Ivanov I, van Damme P, Kojouharova M. Prevalence of HBV and HCV among outpatients in the Plovdiv region of Bulgaria, 2010-2011. *J Med Virol* 2015; **87**: 401-406 [PMID: 25163778 DOI: 10.1002/jmv.24065]

133 **Petrunov B**, Kojouharova M, Teoharov P, Haidushka I, Sotirova P,Sredkova M, Russev I, Zacharakis G, Tzara F, Vafeadis N, Papathanasiou J, Papoutselis K. EU project interreg II: Seroepidemiology study of hepatitis C and B viral infections prevalencein Bulgaria and northern Greece. *J Hepatol* 2002; **36**: Abstract 497

134 **Fitzsimons D**, Kojouharova M, Hallauer J, Hendrickx G, Vorsters A, Van Damme P. Burden and prevention of viral hepatitis in Bulgaria. *Vaccine* 2011; **29**: 8471-8476 [PMID: 21951876 DOI: 10.1016/j.vaccine.2011.09.064]

135 **Voiculescu M**, Iliescu L, Ionescu C, Micu L, Ismail G, Zilisteanu D, Radasan A, Micu G, Pertache I. A cross-sectional epidemiological study of HBV, HCV, HDV and HEV prevalence in the SubCarpathian and South-Eastern regions of Romania. *J Gastrointestin Liver Dis* 2010; **19**: 43-48 [PMID: 20361074]

136 **Gay N**, Edmunds W, Bah E, Nelson C. Estimating the global burden of hepatitis B. World Health Organization, Department of Vaccines and Biologicals, Geneva 2001; 34: 349A

137 **Allain JP**. Epidemiology of Hepatitis B virus and genotype. *J Clin Virol* 2006; **36** Suppl 1: S12-S17 [PMID: 16831687 DOI: 10.1016/S1386-6532(06)80003-X]

138 **Ribeiro NR**, Campos GS, Angelo AL, Braga EL, Santana N, Gomes MM, Pinho JR, De Carvalho WA, Lyra LG, Lyra AC. Distribution of hepatitis B virus genotypes among patients with chronic infection. *Liver Int* 2006; **26**: 636-642 [PMID: 16842318 DOI: 10.1111/j.1478-3231.2006.01280.x]

139 **Milionis C**. Serological markers of Hepatitis B and C among juvenile immigrants from Albania settled in Greece. *Eur J Gen Pract* 2010; **16**: 236-240 [PMID: 20954813 DOI: 10.3109/13814788.2010.525631]

140 **Kondili LA**, Ulqinaku D, Hajdini M, Basho M, Chionne P, Madonna E, Taliani G, Candido A, Dentico P, Bino S, Rapicetta M. Hepatitis B virus infection in health care workers in Albania: a country still highly endemic for HBV infection. *Infection* 2007; **35**: 94-97 [PMID: 17401713 DOI: 10.1007/s15010-007-6076-1]

141 **Chironna M**, Germinario C, Lopalco PL, Quarto M, Barbuti S. HBV, HCV and HDV infections in Albanian refugees in Southern Italy (Apulia region). *Epidemiol Infect* 2000; **125**: 163-167 [PMID: 11057972]

142 **Durro V**, Koraqi A, Saliasi S. Trends in the prevalence of transfusion-transmissible infections among blood donors in Albania. *Clin Lab* 2010; **56**: 591-595 [PMID: 21141446]

143 **Katsanos KH**, Christodoulou DK, Zervou E, Babameto A, Kraja B, Hyphantis H, Karetsos V, Tsonis G, Basho J, Resuli BF, Tsianos EV. Hepatitis B remains a major health priority in Western Balkans: results of a 4-year prospective Greek-Albanian collaborative study. *Eur J Intern Med* 2009; **20**: 698-702 [PMID: 19818290 DOI: 10.1016/j.ejim.2009.07.016]

144 **Kondili LA**, Cuko L, Chionne P, Candido A, Madonna E, Dentico P, Resuli B, Taliani G, Brunetto MR, Rapicetta M. Hepatitis B, C and Delta virus infections in Albanian patients with chronic liver disease: evaluation of possible changes during the last 10 years. *Eur J Gastroenterol Hepatol* 2010; **22**: 167-171 [PMID: 19734797 DOI: 10.1097/MEG.0b013e328330d410]

145 **Resuli B**, Prifti S, Kraja B, Nurka T, Basho M, Sadiku E. Epidemiology of hepatitis B virus infection in Albania. *World J Gastroenterol* 2009; **15**: 849-852 [PMID: 19230046 DOI: 10.3748/wjg.15.849]

146 **Stępień M**, Piwowarow K. Hepatitis B in Poland in 2012. *Przegl Epidemiol* 2014; **68**: 257-63, 363-7 [PMID: 25135511]

147 **Vilibić-Cavlek T**, Kucinar J, Ljubin-Sternak S, Kaić B, Lazarić-Stefanović L, Kolarić B. Prevalence of viral hepatitis in Croatian adult population undergoing routine check-up, 2010-2011. *Cent Eur J Public Health* 2014; **22**: 29-33 [PMID: 24844103]

148 Ежегодный отчет основныхпоказателей здравоохранения [The annual report of the main indicators in public health in Russia]. Moscow, Russia. Vol. 1, Feb 2011. (in Russian)

149 **Schaefer S**. Hepatitis B virus genotypes in Europe. *Hepatol Res* 2007; **37**: S20-S26 [PMID: 17627630 DOI: 10.1111/j.1872-034X.2007.00099.x]

150 **Constantinescu I**, Nedelcu F, Toader MA, Daniela V. Clinical and therapeutical importance of HBV genotyping in Romania. *J Med Life* 2008; **1**: 165-173 [PMID: 20108463]

151 **De Maddalena C**, Giambelli C, Tanzi E, Colzani D, Schiavini M, Milazzo L, Bernini F, Ebranati E, Cargnel A, Bruno R, Galli M, Zehender G. High level of genetic heterogeneity in S and P genes of genotype D hepatitis B virus. *Virology* 2007; **365**: 113-124 [PMID: 17451771 DOI: 10.1016/j.virol.2007.03.015]

152 **Deterding K**, Constantinescu I, Nedelcu FD, Gervain J, Nemecek V, Srtunecky O, Vince A, Grgurevic I, Bielawski KP, Zalewska M, Bock T, Ambrozaitis A, Stanczak J, Takács M, Chulanov V, Slusarczyk J, Drazd'áková M, Wiegand J, Cornberg M, Manns MP, Wedemeyer H. Prevalence of HBV genotypes in Central and Eastern Europe. *J Med Virol* 2008; **80**: 1707-1711 [PMID: 18712830 DOI: 10.1002/jmv.21294]

153 **Olinger CM**, Lazouskaya NV, Eremin VF, Muller CP. Multiple genotypes and subtypes of hepatitis B and C viruses in Belarus: similarities with Russia and western European influences. *Clin Microbiol Infect* 2008; **14**: 575-581 [PMID: 18373690 DOI: 10.1111/j.1469-0691.2008.01988.x]

154 **Slusarczyk J**, Białkowska J, Bucholc B, Wiatrzyk A, Górska P, Jabłkowski M. [HBV genotypes among patients with chronic hepatitis B in the area of central Poland]. *Przegl Epidemiol* 2006; **60**: 555-561 [PMID: 17249180]

155 **Bielawski KP**, Stalke P. Molecular epidemiology of chronic hepatitis B virus infection in northern Poland. *J Clin Virol* 2005; **34** Suppl 1: S63-S69 [PMID: 16461226 DOI: 10.1016/S1386-6532(05)80012-5]

156 **Ciccozzi M**, Babakir-Mina M, Lo Presti A, Salpini R, Cella E, Gabanelli E, Teoharov P, Kevorkyan A, Perno CF, Zehender G, Ciotti M. Molecular analysis of hepatitis B virus in Bulgaria. *J Med Virol* 2013; **85**: 49-54 [PMID: 23154875 DOI: 10.1002/jmv.23432]

157 **Custer B**, Sullivan SD, Hazlet TK, Iloeje U, Veenstra DL, Kowdley KV. Global epidemiology of hepatitis B virus. *J Clin Gastroenterol* 2004; **38**: S158-S168 [PMID: 15602165]

158 **Rantala M**, van de Laar MJ. Surveillance and epidemiology of hepatitis B and C in Europe - a review. *Euro Surveill* 2008; **13**: [PMID: 18761967]

159 **van Houdt R**, Bruisten SM, Geskus RB, Bakker M, Wolthers KC, Prins M, Coutinho RA. Ongoing transmission of a single hepatitis B virus strain among men having sex with men in Amsterdam. *J Viral Hepat* 2010; **17**: 108-114 [PMID: 19811610 DOI: 10.1111/j.1365-2893.2009.01158.x]

160 **Tallo T**, Tefanova V, Priimägi L, Schmidt J, Katargina O, Michailov M, Mukomolov S, Magnius L, Norder H. D2: major subgenotype of hepatitis B virus in Russia and the Baltic region. *J Gen Virol* 2008; **89**: 1829-1839 [PMID: 18632953 DOI: 10.1099/vir.0.83660-0]

161 **Tallo T**, Norder H, Tefanova V, Krispin T, Priimägi L, Mukomolov S, Mikhailov M, Magnius LO. Hepatitis B virus genotype D strains from Estonia share sequence similarity with strains from Siberia and may specify ayw4. *J Med Virol* 2004; **74**: 221-227 [PMID: 15332270 DOI: 10.1002/jmv.20169]

162 **Nardone A**, Anastassopoulou CG, Theeten H, Kriz B, Davidkin I, Thierfelder W, O'Flanagan D, Bruzzone B, Mossong J, Boot HJ, Butur D, Slaciková M, Panait ML, Hellenbrand W, DE Melker H, Sobotová Z, Icardi G, Andrews N, Pebody RG, VAN Damme P, Kafatos G, Miller E, Hatzakis A. A comparison of hepatitis B seroepidemiology in ten European countries. *Epidemiol Infect* 2009; **137**: 961-969 [PMID: 19102797 DOI: 10.1017/S0950268808001672]

163 **Te HS**, Jensen DM. Epidemiology of hepatitis B and C viruses: a global overview. *Clin Liver Dis* 2010; **14**: 1-21, vii [PMID: 20123436 DOI: 10.1016/j.cld.2009.11.009]

164 **Alvarado-Mora MV**, Pinho JR. Epidemiological update of hepatitis B, C and delta in Latin America. *Antivir Ther* 2013; **18**: 429-433 [PMID: 23792375 DOI: 10.3851/IMP2595]

165 **Roman S**, Jose-Abrego A, Fierro NA, Escobedo-Melendez G, Ojeda-Granados C, Martinez-Lopez E, Panduro A. Hepatitis B virus infection in Latin America: a genomic medicine approach. *World J Gastroenterol* 2014; **20**: 7181-7196 [PMID: 24966588 DOI: 10.3748/wjg.v20.i23.7181]

166 **Lavanchy D**. Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention. *J Clin Virol* 2005; **34** Suppl 1: S1-S3 [PMID: 16461208 DOI: 10.1016/S1386-6532(05)00384-7]

167 **Dienstag JL**. Hepatitis B virus infection. *N Engl J Med* 2008; **359**: 1486-1500 [PMID: 18832247 DOI: 10.1056/NEJMra0801644]

168 **Tanaka J**. Hepatitis B epidemiology in Latin America. *Vaccine* 2000; **18** Suppl 1: S17-S19 [PMID: 10683537 DOI: 10.1016/S0264-410X(99)00455-7]

169 **World Health Organization**. International travel and health. Hepatitis B. Available from: URL: http: //www.who.int/ith/diseases/hepatitisB/en/

170 **Roman S**, Tanaka Y, Khan A, Kurbanov F, Kato H, Mizokami M, Panduro A. Occult hepatitis B in the genotype H-infected Nahuas and Huichol native Mexican population. *J Med Virol* 2010; **82**: 1527-1536 [PMID: 20648606 DOI: 10.1002/jmv.21846]

171 **Roman S**, Panduro A, Aguilar-Gutierrez Y, Maldonado M, Vazquez-Vandyck M, Martinez-Lopez E, Ruiz-Madrigal B, Hernandez-Nazara Z. A low steady HBsAg seroprevalence is associated with a low incidence of HBV-related liver cirrhosis and hepatocellular carcinoma in Mexico: a systematic review. *Hepatol Int* 2009; **3**: 343-355 [PMID: 19669360 DOI: 10.1007/s12072-008-9115-9]

172 **Bertolini D**, Moreira R, Soares M, Bensabath G, Lemos M, Mello Imvgc PJ. Genotyping of hepatitis B virus in indigenous populations from Amazon region, Brazil. *Virus Rev Res* 2000; **5** (2-suppl 1): 101

173 **Castilho Mda C**, Oliveira CM, Gimaque JB, Leão JD, Braga WS. Epidemiology and molecular characterization of hepatitis B virus infection in isolated villages in the Western Brazilian Amazon. *Am J Trop Med Hyg* 2012; **87**: 768-774 [PMID: 22908032 DOI: 10.4269/ajtmh.2012.12-0083]

174 **Arauz-Ruiz P**, Norder H, Robertson BH, Magnius LO. Genotype H: a new Amerindian genotype of hepatitis B virus revealed in Central America. *J Gen Virol* 2002; **83**: 2059-2073 [PMID: 12124470]

175 **Devesa M**, Pujol FH. Hepatitis B virus genetic diversity in Latin America. *Virus Res* 2007; **127**: 177-184 [PMID: 17280734 DOI: 10.1016/j.virusres.2007.01.004]

176 **Norder H**, Hammas B, Lee SD, Bile K, Couroucé AM, Mushahwar IK, Magnius LO. Genetic relatedness of hepatitis B viral strains of diverse geographical origin and natural variations in the primary structure of the surface antigen. *J Gen Virol* 1993; **74 ( Pt 7)**: 1341-1348 [PMID: 8336122 DOI: 10.1099/0022-1317-74-7-1341]

177 **Panduro A**, Maldonado-Gonzalez M, Fierro NA, Roman S. Distribution of HBV genotypes F and H in Mexico and Central America. *Antivir Ther* 2013; **18**: 475-484 [PMID: 23792777 DOI: 10.3851/IMP2605]

178 **Zhou Y**, Holmes EC. Bayesian estimates of the evolutionary rate and age of hepatitis B virus. *J Mol Evol* 2007; **65**: 197-205 [PMID: 17684696 DOI: 10.1007/s00239-007-0054-1]

179 **Barbini L**, Elizalde M, Torres C, Campos R. Molecular epidemiology and genetic diversity of hepatitis B virus in Mar del Plata city, Argentina. *Infect Genet Evol* 2013; **19**: 152-163 [PMID: 23871776 DOI: 10.1016/j.meegid.2013.07.007]

180 **Martinez AA**, Zaldivar Y, Hong CCh, Alvarado-Mora MV, Smith R, Ortiz AY, Pinho JR, Cristina J, Pascale JM. Molecular characterisation of hepatitis B virus in the resident Chinese population in Panama City. *Mem Inst Oswaldo Cruz* 2013; **108**: 541-547 [PMID: 23903967 DOI: 10.1590/S0074-02762013000500002]

181 **Khan A**, Tanaka Y, Saito H, Ebinuma H, Sekiguchi H, Iwama H, Wakabayashi G, Kamiya T, Kurbanov F, Elkady A, Mizokami M. Transmission of hepatitis B virus (HBV) genotypes among Japanese immigrants and natives in Bolivia. *Virus Res* 2008; **132**: 174-180 [PMID: 18207274 DOI: 10.1016/j.virusres.2007.12.005]

182 **Roman S**, Fierro NA, Moreno-Luna L, Panduro A. Hepatitis B virus genotype H and environmental factors associated to the low prevalence of hepatocellular carcinoma in Mexico. *J Cancer Ther* 2013; **2A**: 367-376 [DOI: 10.4236/jct.2013.42A044]

183 **Pujol FH**, Roman S, Panduro A, Navas MC, Lampe E. Hepatocellular carcinoma in Latin America. Isabelle Chemin, Ed In: Hepatocellular Carcinoma: A Global Challenge. NewYork: Nova Science Publishers Inc, 2012: 55-68

184 **Torres JR**. Hepatitis B and hepatitis delta virus infection in South America. *Gut* 1996; **38** Suppl 2: S48-S55 [PMID: 8786054 DOI: 10.1136/gut.38.Suppl\_2.S48]

185 **Braga WS**, Castilho Mda C, Borges FG, Martinho AC, Rodrigues IS, Azevedo EP, Scazufca M, Menezes PR. Prevalence of hepatitis B virus infection and carriage after nineteen years of vaccination program in the Western Brazilian Amazon. *Rev Soc Bras Med Trop* 2012; **45**: 13-17 [PMID: 22370822 DOI: 10.1590/S0037-86822012000100004]

186 **de la Hoz F**, Perez L, de Neira M, Hall AJ. Eight years of hepatitis B vaccination in Colombia with a recombinant vaccine: factors influencing hepatitis B virus infection and effectiveness. *Int J Infect Dis* 2008; **12**: 183-189 [PMID: 17913535 DOI: 10.1016/j.ijid.2007.06.010]

 **P-Reviewer:** Long QX, Nguyen vb **S-Editor:** Ma YJ **L-Editor:** **E-Editor:**

**Table 1 Prevalence of hepatitis B virus infection and genotype distribution in some African countries**

|  |  |  |
| --- | --- | --- |
| **Countries** | **HBsAg-positive prevalence1**  | **HBV genotype distribution2** |
| Burkina Faso | 14.5% | **A**: A1 southern and eastern  Africa A2 South Africa**D**: D1 and D7 northern Africa**E**: western and central AfricaRecombinant **A/D** and **A/E**   |
| Cameroon | 10.1% |
| Gabon | 9.5% |
| Ghana | 13.8% |
| Mali | 15.5% |
| Mauritania | 10.9% |
| Nigeria | 13.6% |
| Senegal  | 13.8% |
| Zambia | 6.5% |
| Zimbabwe | 25% |

1Ref. [4,11]; 2Ref [66,68-73,75,77]. HBsAg: hepatitis B surface antigen; HBV: hepatitis B virus.

**Table 2 Prevalence of hepatitis B virus infection and genotype distribution in some Asian countries**

|  |  |  |
| --- | --- | --- |
| **Countries** | **HBsAg-positive prevalence1**  | **HBV genotype distribution2** |
| Cambodia | 4.6% | **A:** India A1 India**B:** China B2 southern China **C**: China C1 southern China, India C2 northern China**D:** Arabian countries and India D1 Persian Gulf (Iran,  Syria, Turkey), India, Pakistan D2,D3,D4,D9 India**C/D1- CD2** western China  |
| China | 7.18% |
| Gaza Strip | 3.5% |
| India | 3.7% |
| Iraq | 0.6% |
| Jordan | 1.4% |
| Kazakhstan | 3.8% |
| Kuwait | 3.5% |
| Saudi Arabia | 1.5-2.6% |
| Singapore | 3.6% |
| South Korea | 4 % |
| United Arab Emirates | 2-7% |
| Yemen | 5.1% |

1Ref. [16,85-92,96,99,105-108]; 2Ref [109-118,121,123,125]. HBsAg: hepatitis B surface antigen; HBV: hepatitis B virus.

**Table 3 Prevalence of hepatitis B virus infection and genotype distribution in some eastern European countries**

|  |  |  |
| --- | --- | --- |
| **Countries** | **HBsAg prevalence1**  | **HBV genotype distribution2** |
| Albania | > 9% | **A**: Eastern Europe (Poland,  Czech Republic, Bulgaria,  Hungary3) A2Bulgaria**D**: Southeastern Europe (Russia, the Baltic region, Belarus, Romania, Hungary,  Serbia, Croatia, Lithuania, Romania, Bulgaria)3 D1 Bulgaria D2 Albania, Russia,  Estonia, the Siberian and  eastern part of the  former USSR  D3 Serbia[D: prevalent genotype (70%-80%)]3A,D: equal distribution  |
| Bulgaria | 3.8% |
| Croatia | 1.7%-15.8% |
| Poland | 3.91/1000003 |
| Romania | 5.59% |
| Russia | 7.6/100000 |
| Serbia | 4.4%-13% |

1Ref. [133-138,142-145,147,148]; 2Ref [150-156,160,161]; 3incidence/year. HBsAg: hepatitis B surface antigen; HBV: hepatitis B virus.

**Table 4 Prevalence of hepatitis B virus infection and genotype distribution in some Latin American countries**

|  |  |  |
| --- | --- | --- |
| **Countries** | **HBsAg prevalence1**  | **HBV genotype distribution2** |
| Mexico, Honduras, Nicaragua, Costa Rica, Panama, Uruguay, Chile, Argentina, Peru, northern Colombia | Low prevalence (< 2%) | **F**: F1 Central America eastern South- America F2 Venezuela, Brazil F3 Central (Panama) and  northern (Colombia and  Venezuela) Latin America F4 Bolivia and Argentina**(F genotype: prevalent)****H**: Amerindians and Mestizios  in Mexico**A,D:** Gualalajara, Jalisco, Mexico, Argentina**B,C:** dispersed among Latin America  populations (due to Asian  immigrants)  |
| Central America: Guatemala, El Salvador, Honduras, Haiti, Dominican Republic, Puerto RicoSouth America: Ecuador, French Guyana, Suriname, south Brazil | Intermediate prevalence (> 2%< 8%) |
| Northern Brazil, southern Colombia, Peru, northern Bolivia | High prevalence (> 8%) |

1Ref. [166-169]; 2Ref. [177,178]. HBsAg: hepatitis B surface antigen; HBV: hepatitis B virus.